Changes in Beneficial Ownership · 4
Mineralys Therapeutics, Inc.
MLYSNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1790117313.xml
Filing details
- Report period
- 2026-09-21
- Issuer
- Mineralys Therapeutics, Inc.
- Issuer CIK
- 0001933414
- Trading symbol
- MLYS
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Warren Eric
- Reporting owner CIK
- 0001916048
- Relationship
- Officer
- Officer title
- Chief Commercial Officer
- Address
- 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR, PA, 19087
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-21 | M · Form 4[F1] | 7,438 | A | 13.24 | 45,838 | D |
| Common Stock | 2026-09-21 | S · Form 4[F1] | 7,438 | D | 28.1172[F2] | 38,400 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | 13.24 | 2026-09-21 | M · Form 4[F1] | 7,438 | D | 0 | [F3] | 2035-04-21 | Common Stock | 7,438 | 230,563 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.↩ 1↩ 2↩ 3
- F2
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.↩ 1
- F3
- The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.↩ 1
Signature 1
- Signed
- /s/ Adam Levy, Attorney-in-fact
- Date
- 2026-09-22
Company context
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.